Clinical trials: GBM
Gut Microbiota, Glioblastoma Multiforme, Microglia, Tumor Related Macrophagocyte, Prognosis
Gut Microbiota and Glioblastoma Multiforme Prognosis
Glioma is the most common primary cancer of the central nervous system, and around 50% of patients present with the most aggressive form of the disease, glioblastoma.
- Trial name
- NCT03631823
- Testing
- Chemotherapy with temozolomide or no chemotherapy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Glioblastoma, Glioma
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness
Tumors of the central nervous system affect 21 people per 100,000 every year, a figure that refers to countries with advanced economies, with an increase in incidence over time.
- Conditions
- Glioblastoma, Glioma, Glioma Glioblastoma Multiforme
- Trial name
- NCT06348693
- Testing
- cell isolation from tumor biopsies and biomarker investigation
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Glioblastoma
Expectations and Needs of a Glioblastoma Caregiver
Cancers of the central nervous system have a poor prognosis. Glioblastoma is most common glial tumor of the central nervous system.
- Trial name
- GLOIOS (NCT06490497)
- Testing
- Interview
- Where
- France
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Hopital Nord Franche-Comte
Brain Metastases, Cancer
Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR
The purpose of this study is to assess the relationship between brain malignancy volume as defined by post-contrast T1 weighted and F18 Fluciclovine before and following LITT.
- Conditions
- Brain Metastases, Cancer, Gliomas, Glioblastoma
- Trial name
- NCT05054400
- Testing
- F18 Fluciclovine, Standard of Care
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Glioblastoma
Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer
This study evaluates how useful and acceptable the components of the "Couples Coping Together Against Cancer", referred to as "The Program", are to the participants with cancer.
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Glioblastoma, Lung Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT07664579
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Glioblastoma
Immuno-Positron Emission Tomography (PET)-Glioma Study, a Proof-of-principle Imaging Study
Imaging of proinflammatory activated microglia by Purine 2X7 (P2X7) receptor scintigraphy in Positron Emission Tomography (PET) scanner in Glioblastoma patients.
- Trial name
- NCT05753995
- Testing
- PET imaging
- Where
- Austria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kepler University Hospital
Glioblastoma
IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Glioblastoma
This is an open-label positron emission tomography/near infrared (PET/NIRF) study to investigate the imaging navigation performance and evaluation efficacy of dual modality imaging probe 68Ga-BBN-IRDye800CW in glioblastoma (GBM)…
- Trial name
- NCT02910804
- Testing
- 68Ga-BBN-IRDye800CW, PET/NIRF, PET/NIR fluorescent imaging-guided surgery
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma
- Trial name
- NCT06333899
- Testing
- Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Nationwide Children's Hospital
Glioma
Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion
this study will investigate the relationship between tumor stiffness and adhesion in gliomas using MRE. By utilizing preoperative MRE and Intraoperative neuronavigation, followed by comprehensive molecular pathology analysis, we…
- Trial name
- NCT05990244
- Testing
- Magnetic Resonance Elastography, Assessment and Recording
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Glioblastoma, WHO Grade II Glioma
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
This trial studies whether a customized video intervention can help to reduce anxiety in brain cancer patients undergoing radiation treatment and their caregivers.
- Conditions
- Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma
- Trial name
- NCT04479696
- Testing
- Educational Intervention, Questionnaire Administration, Survey Administration
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme, Anaplastic Astrocytoma
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma
- Trial name
- NCT05956821
- Testing
- SIACI of cetuximab and bevacizumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Miami
Glioblastoma Multiforme, Healthy Volunteers
Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients
The purpose of this study is to determine if tumor cells can be detected in the blood of patients diagnosed with a brain tumor.
- Trial name
- NCT01135875
- Testing
- GBM Patients, Normal Controls
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Florida
Brain Cancer
A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients
The study is designed to evaluate how the composition of a participant's body, diagnosed with a brain tumor (glioblastoma multiforme) as determined by bioelectrical impedance analysis can predict the progression and outcomes of…
- Trial name
- BEAM (NCT01770626)
- Testing
- Nutrition
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Glioblastoma Multiforme
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
A Phase II, multi-center, open-label, single-arm study in up to 42 subjects with first recurrence or progression of GBM at up to 12 sites in Australia, Europe, Israel, and the United States.
- Trial name
- CLARITY-1 (NCT00797940)
- Testing
- IL-4PE
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Brain Tumor Adult
Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma
This study is being conducted to find out if the safety and tolerability of an experimental cell therapy is safe to administer to patients with a newly diagnosed glioblastoma multiforme (GBM) in combination with temozolomide…
- Trial name
- DRI (NCT04165941)
- Testing
- DRI cell therapy
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Glioblastoma, Gliosarcoma
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Primary objective: To evaluate activity of imatinib mesylate and hydroxyurea among patients with progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month progression free survival Secondary objectives: To…
- Trial name
- NCT00615927
- Testing
- Imatinib Mesylate & Hydroxyurea
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Duke University
Healthy Subject, Intracranial Neoplasm
[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
This phase I trial studies how well [18F]DASA-23 and positron emission tomography (PET) scan work in evaluating pyruvate kinase M2 (PKM2) expression in patients with intracranial tumors or recurrent glioblastoma and healthy…
- Conditions
- Healthy Subject, Intracranial Neoplasm, Glioblastoma
- Trial name
- NCT03539731
- Testing
- Fluorine F 18 DASA-23, Positron Emission Tomography
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Guido A. Davidzon, MD, SM
Carcinoma, Glioblastoma
MRinRT: Swansea University and SWWCC Collaboration Study.
The aim of this study is to learn whether using MRI (magnetic resonance imaging) scans to plan radiotherapy is better than using CT (computed tomography) scans alone.
- Conditions
- Carcinoma, Glioblastoma, Radiotherapy, MRI
- Trial name
- MRinRT (NCT07365124)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Swansea Bay University Health Board
Breast Cancer, Non-Small-Cell Lung Cancer
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
The purpose of the study was to conduct a pilot test of new tracers ([18F]FPRGD2 and [18F]FPPRGD2) to define normal tracer biodistribution (where the tracer goes), stability (how much metabolises), pharmacokinetics (how much…
- Conditions
- Breast Cancer, Non-Small-Cell Lung Cancer, Glioblastoma, Other Cancers
- Trial name
- NCT01383135
- Testing
- F18-FPPRGD2
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Stanford University
Lupus Nephritis
Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?
Introduction and background : Glomerulonephritis and auto-immune diseases are often associated. Lupus nephritis (LN) is one of the major clinical manifestations of systemic lupus erythematosus (SLE) which have a severe impact on…
- Trial name
- GOODLUPUS (NCT03664908)
- Testing
- Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CHU de Reims